Strategy of Suppressing Myopia Progression in Children With Atropine: A Systematic Review
Main Article Content
Introduction: The prevalence of myopia in children has been a global issue in recent decades. Atropine is becoming more popular in suppressing myopia progression. Still, there is no clear guidance regarding the timing of commencement and cessation, as well as the duration of treatment. Objectives: To assess the timing and regimen of atropine therapy in myopia progression, response towards therapy, and rebound phenomenon. Method: A comprehensive literature search (Cochrane®, Pubmed®, and ProQuest®) was performed using relevant search terms. Inclusion criteria included randomized controlled trials and cohorts of myopic children undergoing atropine therapy. Conference abstracts, case reports, and duplicate publications were excluded. The primary outcome is identifying the optimal treatment regimen. The secondary outcome is the evaluation of the rebound effect. Results: Some studies revealed that atropine can be administered once myopia progression is diagnosed, as early as 4 years old. Yet younger age would apt to rebound. The administration suggestion is the 2-year period with 6 monthly follow-ups, with increasing concentration if myopia continues to progress. Tapering off recommendations differs by population. Higher concentrations were prone to rebound, hence lower concentrations (0.01%) maintain better clinical efficacy with minimal side effects. However, another study revealed that a higher myopia baseline requires a slightly higher dose (0.05%) for its axial elongation suppression, with tolerable pupil size and accommodation. Although atropine showed more progression after cessation compared to placebo (-1.14±0.80D vs. -0.38±0.39D), absolute progression significantly lowered after 3 years (-4.29±1.67D vs. -5.22±1.38D). Conclusion: Atropine is widely used and appears to be effective in controlling myopia in children with appropriate doses and proper duration of treatment to minimize rebound.
Chia, A., Lu, Q.-S., & Tan, D. (2016). Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2. Ophthalmology, 123(2), 391–399. https://doi.org/10.1016/j.ophtha.2015.07.004
Fu, A., Stapleton, F., Wei, L., Wang, W., Zhao, B., Watt, K., Ji, N., & Lyu, Y. (2020). Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. British Journal of Ophthalmology, 104(11), 1535–1541.
Fudin, H. R., Babin, J. L., Hong, L. T., Ku, J., May, A. L., Wisner, A., Scott Hall, F., & Ray, S. D. (2018). Drugs of Abuse (pp. 29–89). https://doi.org/10.1016/bs.seda.2018.08.015
Garcia Del Valle, I., & Alvarez-Lorenzo, C. (2021). Atropine in topical formulations for the management of anterior and posterior segment ocular diseases. Expert Opinion on Drug Delivery, 18(9), 1245–1260.
Hiebl, M. R. W. (2023). Sample selection in systematic literature reviews of management research. Organizational Research Methods, 26(2), 229–261.
Jawaid, I., Saunders, K., Hammond, C. J., Dahlmann-Noor, A., & Bullimore, M. A. (2024). Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners. Eye, 38(3), 434–441.
Joachimsen, L., Farassat, N., Bleul, T., Böhringer, D., Lagrèze, W. A., & Reich, M. (2021). Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study. International Ophthalmology, 41, 2001–2008.
Khanal, S., & Phillips, J. R. (2020a). Which low?dose atropine for myopia control? Clinical and Experimental Optometry, 103(2), 230–232.
Khanal, S., & Phillips, J. R. (2020b). Which low?dose atropine for myopia control? Clinical and Experimental Optometry, 103(2), 230–232.
Li, F. F., Zhang, Y., Zhang, X., Yip, B. H. K., Tang, S. M., Kam, K. W., Young, A. L., Chen, L. J., Tham, C. C., Pang, C. P., & Yam, J. C. (2021). Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine. Ophthalmology, 128(8), 1180–1187. https://doi.org/10.1016/j.ophtha.2020.12.036
Medina, A. (2022). The cause of myopia development and progression: Theory, evidence, and treatment. Survey of Ophthalmology, 67(2), 488–509. https://doi.org/10.1016/j.survophthal.2021.06.005
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., & Daley, C. L. (2019). Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 200(10), e93–e142.
Polling, J. R., Kok, R. G. W., Tideman, J. W. L., Meskat, B., & Klaver, C. C. W. (2016). Effectiveness study of atropine for progressive myopia in Europeans. Eye, 30(7), 998–1004.
Sander, B. P., Collins, M. J., & Read, S. A. (2019). Short?term effect of low?dose atropine and hyperopic defocus on choroidal thickness and axial length in young myopic adults. Journal of Ophthalmology, 2019(1), 4782536.
Tomiyama, E. S., Berntsen, D. A., & Richdale, K. (2022). Peripheral refraction with toric orthokeratology and soft toric multifocal contact lenses in myopic astigmatic eyes. Investigative Ophthalmology & Visual Science, 63(8), 10.
Wang, S. K., Guo, Y., Liao, C., Chen, Y., Su, G., Zhang, G., Zhang, L., & He, M. (2018). Incidence of and factors associated with myopia and high myopia in Chinese children, based on refraction without cycloplegia. JAMA Ophthalmology, 136(9), 1017–1024.
Wong, Y.-L., & Saw, S.-M. (2016). Epidemiology of Pathologic Myopia in Asia and Worldwide. Asia-Pacific Journal of Ophthalmology, 5(6), 394–402. https://doi.org/10.1097/APO.0000000000000234
Xiong, S., Sankaridurg, P., Naduvilath, T., Zang, J., Zou, H., Zhu, J., Lv, M., He, X., & Xu, X. (2017). Time spent in outdoor activities in relation to myopia prevention and control: a meta?analysis and systematic review. Acta Ophthalmologica, 95(6), 551–566.
Yam, J. C., Li, F. F., Zhang, X., Tang, S. M., Yip, B. H. K., Kam, K. W., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., & Pang, C. P. (2020). Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology, 127(7), 910–919. https://doi.org/10.1016/j.ophtha.2019.12.011.
